Events

COST Belgian Info Day 2025
MAY
Wed
07
10:00 - 15:00

This was 8 months ago

Location

WTC III

BOSA
Room Tahiti (2nd floor)
Simon Bolivarlaan 30
1000 Brussels
Programmes
COST

The Belgian COST Contact Points will organise a COST Info Day on 7 May 2025 (10:00-15:00) in WTC III (Simon Bolivarlaan 30, 1000 Brussels). The info day will consist of two sessions:

  • general session in which COST and its networking opportunities will be presented.
  • specialised session for Belgian researchers and innovators that are preparing a COST proposal as the 'main proposer' or ‘secondary proposer’. The deadline of the next COST Open Call is 21 October 2025 at 12.00 (noon) CEST. More information here.

More information on the agenda and registration can be found here. Please register by 30 April 2025.

For questions related to this event and the COST Programme, please contact cost@fwo.be.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.